Cargando…
Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19
BACKGROUND AND OBJECTIVES: : In this moments, of extreme gravity in which we find ourselves, and in the uncertainty face about the most effective treatment against COVID-19 disease and with the aim of find the evidence that support the chloroquine/hydroxychloroquine use recommendation to treat COVID...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837044/ https://www.ncbi.nlm.nih.gov/pubmed/32739134 http://dx.doi.org/10.1016/j.semerg.2020.06.016 |
_version_ | 1783642877040001024 |
---|---|
author | Mayayo-Vicente, S. Rodriguez Salvanés, F. Gallego-Arenas, A. Sánchez-Gómez, L.M. Ruiz-López, M. Sierra García, B. Jurado-López, A. Arriola-Bolado, P. Cervera Cano, M. Novella-Arribas, B. |
author_facet | Mayayo-Vicente, S. Rodriguez Salvanés, F. Gallego-Arenas, A. Sánchez-Gómez, L.M. Ruiz-López, M. Sierra García, B. Jurado-López, A. Arriola-Bolado, P. Cervera Cano, M. Novella-Arribas, B. |
author_sort | Mayayo-Vicente, S. |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: : In this moments, of extreme gravity in which we find ourselves, and in the uncertainty face about the most effective treatment against COVID-19 disease and with the aim of find the evidence that support the chloroquine/hydroxychloroquine use recommendation to treat COVID-19 disease, a systematic review of published studies and RCT studies publishes until April 28, 2020 was carried out. MATERIAL AND METHODS: A systematic search was carried out in PubMed with the keywords COVID-19 and their synonyms and hydroxychloroquine/chloroquine. The data selection and extraction was elaborated by two researchers, independently. The results were discussed with a Primary Care physicians clinical group and the results were synthesized using GRADE methodology. RESULTS: A good quality systematic review was found that includes articles with a high risk of bias. And 8 EC launched that will produce results beyond May 2020. CONCLUSIONS: Although the conclusions of the systematic review generate a low confidence in the results, and the clinical variables that show benefit are intermediate variables, the side effects are acceptable and could be minimized with the use of QT lengthening risk tools, so it is could make a weak recommendation in favor of the use of chloroquine/hydroxychloroquine in patients with mild-moderate stage COVID-19. |
format | Online Article Text |
id | pubmed-7837044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78370442021-01-26 Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19 Mayayo-Vicente, S. Rodriguez Salvanés, F. Gallego-Arenas, A. Sánchez-Gómez, L.M. Ruiz-López, M. Sierra García, B. Jurado-López, A. Arriola-Bolado, P. Cervera Cano, M. Novella-Arribas, B. Semergen Original BACKGROUND AND OBJECTIVES: : In this moments, of extreme gravity in which we find ourselves, and in the uncertainty face about the most effective treatment against COVID-19 disease and with the aim of find the evidence that support the chloroquine/hydroxychloroquine use recommendation to treat COVID-19 disease, a systematic review of published studies and RCT studies publishes until April 28, 2020 was carried out. MATERIAL AND METHODS: A systematic search was carried out in PubMed with the keywords COVID-19 and their synonyms and hydroxychloroquine/chloroquine. The data selection and extraction was elaborated by two researchers, independently. The results were discussed with a Primary Care physicians clinical group and the results were synthesized using GRADE methodology. RESULTS: A good quality systematic review was found that includes articles with a high risk of bias. And 8 EC launched that will produce results beyond May 2020. CONCLUSIONS: Although the conclusions of the systematic review generate a low confidence in the results, and the clinical variables that show benefit are intermediate variables, the side effects are acceptable and could be minimized with the use of QT lengthening risk tools, so it is could make a weak recommendation in favor of the use of chloroquine/hydroxychloroquine in patients with mild-moderate stage COVID-19. Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. 2020-08 2020-07-11 /pmc/articles/PMC7837044/ /pubmed/32739134 http://dx.doi.org/10.1016/j.semerg.2020.06.016 Text en © 2020 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Published by Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Mayayo-Vicente, S. Rodriguez Salvanés, F. Gallego-Arenas, A. Sánchez-Gómez, L.M. Ruiz-López, M. Sierra García, B. Jurado-López, A. Arriola-Bolado, P. Cervera Cano, M. Novella-Arribas, B. Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19 |
title | Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19 |
title_full | Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19 |
title_fullStr | Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19 |
title_full_unstemmed | Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19 |
title_short | Tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de COVID-19 |
title_sort | tratamiento farmacológico en tiempos de incertidumbre: uso de la hidroxicloroquina/cloroquina en el tratamiento de covid-19 |
topic | Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837044/ https://www.ncbi.nlm.nih.gov/pubmed/32739134 http://dx.doi.org/10.1016/j.semerg.2020.06.016 |
work_keys_str_mv | AT mayayovicentes tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19 AT rodriguezsalvanesf tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19 AT gallegoarenasa tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19 AT sanchezgomezlm tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19 AT ruizlopezm tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19 AT sierragarciab tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19 AT juradolopeza tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19 AT arriolaboladop tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19 AT cerveracanom tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19 AT novellaarribasb tratamientofarmacologicoentiemposdeincertidumbreusodelahidroxicloroquinacloroquinaeneltratamientodecovid19 |